|1||Cryptococcal meningitis and maintenance therapy to prevent relapse of cryptococcal disease in patients with AIDS.|
|3||Oropharyngeal and oesophageal candidiasis.|
|4||Prevention of fungal infections in patients with malignancy who are predisposed to such infections as a result of cytotoxic chemotherapy and radiotherapy.|
|1||Vaginal candidiasis, acute or recurrent and prophylaxis to reduce the incidence of recurrent vaginal candidiasis.|
|3||Dermatomycosis including tinea cruris, tinea corporis, tinea pedis, tinea unguium (onychomycosis), and dermal candida infection.|
|Creatinine Clearance (mL/min)||Percent of Recommended Dose|
|Regular haemodialysis||100% after each dialysis|
|Males:||Weight (kg) x (140 minus age)|
|72 x serum creatinine (mg/dL)|
|Weight (kg) x (140 minus age)|
|88,4 x 72 x serum creatinine (mg/dL)|
|Females:||0.85 x above value|
|1||Cryptococcal meningitis may be treated with an initial dose of fluconazole 400 mg on the first day followed by 200 mg once daily. |
This dose may be increased to 400 mg daily, depending on the clinical response of the patient.
The duration of therapy for cryptococcal meningitis is based on clinical and mycological response, but is usually 6-8 weeks.
Fluconazole may also be used in daily doses of 100 to 200 mg to prevent relapse following a primary course of antifungal therapy for acute cryptococcal meningitis in patients with AIDS.
|2||Systemic candidiasis may be treated with an initial dose of fluconazole 400 mg on the first day followed by 200 mg daily. The dose may be increased to 400 mg daily, depending on the clinical response of the patient. Duration of therapy for systemic candidiasis treatment is based on the clinical response of the patient.|
|3||For oropharyngeal candidiasis, the usual dose is 50 to 100 mg once daily for 7-14 days. In patients with severely compromised immune function, treatment can be continued for longer periods if necessary.|
In patients with AIDS, after the patient receives a full course of primary therapy, fluconazole may be administered at a 150 mg once weekly dose in order to prevent a relapse of oropharyngeal candidiasis.
For oesophageal candidiasis, the recommended dose is 200 mg on the first day, followed by 100 mg to 200 mg once daily.
Doses of up to 400 mg daily may be used based on medical judgement of the patients response to therapy.
Patients with oesophageal candidiasis should be treated for a minimum of three weeks and for at least two weeks following resolution of symptoms.
|4||For the prevention of candidiasis, a fluconazole dosage of 50 mg to 400 mg once daily is recommended based on the patients risk for developing fungal infection. |
A dose of 400 mg once daily has been used in patients who are at high risk of systemic infection e.g. patients who are anticipated to have profound or prolonged neutropenia.
Fluconazole administration should commence several days before the anticipated onset of neutropenia and continue for 7 days after the neutrophil count rises above 1000 cells per mm³.
|5||Fluconazole 150 mg should be administered as a single oral dose for vaginal candidiasis.|
A 150 mg once monthly dose may be used to reduce the incidence of recurrent vaginal candidiasis. Individualisation of the duration of therapy is necessary but ranges from 4-12 months. Some patients may require more frequent dosing.
|6||Fluconazole 150 mg should be administered as a single oral dose, for the treatment of candida balanitis.|
|7||For dermal infections including tinea cruris, pedis, corporis, and candida infections the recommended dosage is 150 mg once weekly. The recommended duration of therapy is normally 2 to 4 weeks. Tinea pedis may require treatment for up to 6 weeks.|
The recommended dosage for tinea unguium is 150 mg once weekly. Treatment should be continued until infected nail is replaced (uninfected nails grow in). Re-growth of fingernails and toenails normally require 3 to 6 months and up to 6 to 12 months, respectively. However, growth rates may vary widely in individuals and by age. Nails occasionally remain disfigured after successful treatment of long term chronic infections.
|1||For the treatment of oropharyngeal candidiasis in children, the recommended fluconazole dosage is 6 mg/kg on the first day, followed by 3 mg/kg once daily. To lower the likelihood of relapse, treatment should be administered for at least 2 weeks.|
|2||For the treatment of oesophageal candidiasis in children, the recommended fluconazole dosage is 6 mg/kg on the first day, followed by 3 mg/kg once daily. |
Based on medical judgment of the patients response, doses up to 12 mg/kg/day may be used.
Patients with oesophageal candidiasis should be treated for a minimum of three weeks and for at least 2 weeks following the resolution of symptoms.
|3||For the treatment of systemic candidiasis and cryptococcal infection, the recommended dosage is 6-12 mg/kg/day, depending on the severity of the disease.|
|4||For the prevention of fungal infections in immunocompromised patients considered at risk as a consequence of neutropenia following cytotoxic chemotherapy or radiotherapy, the dose should be 3-12 mg/kg daily, depending on the extent and duration of the induced neutropenia.|
(For children with impaired renal function, see Dosage in patients with impaired renal function).
|3||Ringer lactate solution|
|4||Isotonic sodium chloride solution|
|5||Sodium hydrogen carbonate 4,2%|
|6||Potassium chloride in glucose|
|FLUZOL 50 mg CAPSULES||Hard gelatin capsules, snap-fit closure, turquoise cap/white body with the imprint FC50, containing a white odourless powder.|
|FLUZOL 150 mg CAPSULES||Hard gelatin capsules, snap-fit closure, white cap/white body with the imprint FC150, containing a white odourless powder.|
|FLUZOL 200 mg CAPSULES||Hard gelatin capsules, snap-fit closure, purple cap/white body with the imprint FC200, containing a white odourless powder.|
|FLUZOL IV INFUSION 100 mL||Clear glass vials containing a clear, colourless solution, free from visible particles.|
|FLUZOL 50 mg CAPSULES||White, opaque PVC/Aluminium blisters strips containing 14 capsules|
|FLUZOL 150 mg CAPSULES||White, opaque PVC/Aluminium blisters strips containing 1 or 4 capsules|
|FLUZOL 200 mg CAPSULES||White, opaque PVC/Aluminium blisters strips containing 28 or 30 capsules|
|FLUZOL IV INFUSION 100 mL||100 mL clear glass vials containing clear, colourless solution, free from visible particles|
|FLUZOL 50 mg, 150 and 200 CAPSULES||Store below 25°C. |
Do not remove the blisters from the outer container until required for use.
Keep out of reach of children.
|FLUZOL IV INFUSION||Store below 25°C.|
Do not freeze. Discard remaining contents after use.
Keep out of reach of children.
|FLUZOL 50 mg CAPSULES||36/20.2.2/0261|
|FLUZOL 150 mg CAPSULES||36/20.2.2/0262|
|FLUZOL 200 mg CAPSULES||36/20.2.2/0263|
|FLUZOL IV INFUSION 100 mL||37/20.2.2/0033|